H.C. Wainwright lowered the firm’s price target on Harmony Biosciences (HRMY) to $55 from $70 and keeps a Buy rating on the shares. The firm removed ZYN002 from its model after the Phase 3 RECONNECT trial missed the endpoint.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Sell Rating for Harmony Biosciences: Setbacks in R&D and Uncertain Pipeline Outlook
- Harmony Biosciences Phase 3 Study Misses Endpoint
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
- Micron reports Q4 beat, Instagram reports 3B MAUs: Morning Buzz
- Harmony Biosciences Holdings: Strong Buy Rating Backed by Wakix Success and Robust Pipeline